Trial Profile
Multicenter, Double-Blind, Randomized, 2-Arm, Parallel-Group, Equivalence Study Evaluating Efficacy and Safety Similarity of Mylan Adalimumab (MYL-1401A) Compared With Humira in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Mylan
- 02 May 2017 Status changed from active, no longer recruiting to completed.
- 06 Apr 2017 This trial has been completed in Bulgaria and Hungary (End date:2017-03-06) as per European Clinical Trials Database record.
- 01 Apr 2017 Trial status is completed in Estonia (end date: 2017-03-06) as per European Clinical Trials Database record.